Mass spectrometry‐based secretome analysis of non‐small cell lung cancer cell lines
Authors:
- 21 September 2016
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 16 (21) , 2801-2814
Abstract
Tyrosine kinase inhibitors, such as erlotinib, display reliable responses and survival benefits for the treatment of human non‐small cell lung cancer (NSCLC) patients. However, primary or acquired resistance limits their therapeutic success. In this study, we conducted in‐depth mass spectrometric analyses of NSCLC cell secretomes. To identify secreted proteins that are differentially regulated in erlotinib‐sensitive (PC‐9) and ‐resistant (PC‐9ER) NSCLC cell lines, SILAC experiments were performed. On average, 900 proteins were identified in each sample with low variations in the numbers of identified proteins. Fourteen proteins were found to be differently regulated among erlotinib‐sensitive and ‐resistant NSCLC cell lines, with five proteins (tissue‐type plasminogen activator, epidermal growth factor receptor, urokinase‐type plasminogen activator, platelet‐derived growth factor D, and myeloid‐derived growth factor) showing the most prominent regulation. Tissue‐type plasminogen activator (t‐PA) was up to 10‐times upregulated in erlotinib‐resistant NSCLC cells compared with erlotinib‐sensitive cells. T‐PA is an established tumor marker for various cancer types and seems to be a promising prognostic marker to differentiate erlotinib‐sensitive from erlotinib‐resistant NSCLC cells. To gain further insights into t‐PA‐regulated pathways, a t‐PA variant was expressed in E. coli cells and its interactions with proteins secreted from erlotinib‐sensitive and ‐resistant NCSLC cells were studied by a combined affinity enrichment chemical cross‐linking/mass spectrometry (MS) approach. Fourteen proteins were identified as potential t‐PA interaction partners, deserving a closer inspection to unravel the mechanisms underlying erlotinib resistance in NSCLC cells.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Projects Si 867/14‐1, 15‐2)
This publication has 66 references indexed in Scilit:
- Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung CarcinomaPLOS ONE, 2012
- Human periprostatic white adipose tissue is rich in stromal progenitor cells and a potential source of prostate tumor stromaExperimental Biology and Medicine, 2012
- In vivo protein complex topologies: Sights through a cross‐linking lensProteomics, 2012
- Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locationsCancer Letters, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- SRSF1 Regulates the Alternative Splicing of Caspase 9 Via A Novel Intronic Splicing Enhancer Affecting the Chemotherapeutic Sensitivity of Non–Small Cell Lung Cancer CellsMolecular Cancer Research, 2011
- Syndecan-1 and Syndecan-4 Are Independent Indicators in Breast CarcinomaJournal of Histochemistry & Cytochemistry, 2011
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor PathwayClinical Lung Cancer, 2009
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1Cancer Research, 2007